Project Grant K22AI187532
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of the University of Pennsylvania $3.16 million on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immune imprinting and cross-reactive antibody responses to pandemic influenza viruses. The research examines how childhood exposure to seasonal influenza viruses creates long-lived immunological imprints that may provide protection against novel pandemic...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital of Philadelphia $906,255 on July 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to discover and characterize novel genes regulating follicular helper T cell function in antibody responses. The research combines variant-to-gene mapping approaches in human follicular helper T cells to identify disease-associated genetic variation influencing B cell antibody responses. Aim...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $130,564 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate host determinants of enterovirus D68 immunity and neuropathogenesis. The research employs mouse models inoculated with enterovirus D68 strains to assess viral tropism, virulence, and immune mechanisms underlying paralysis. Preliminary findings demonstrate that virulent strains localize to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $762,086 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify signaling networks that contribute to TH17-mediated neuroinflammation in multiple sclerosis. The recipient will develop a comprehensive suite of mass spectrometry proteomics tools to characterize protein abundance and phosphorylation in pathogenic TH17 cells at the systems level using the...
- The National Institute of Allergy and Infectious Diseases awarded the University of Alabama at Birmingham $490,611 on April 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of regulatory dendritic cells in neonatal immune responses to influenza infection. The research examines how a newly identified form of dendritic cell maturation (mREGDC1) impairs protective CD8 T cell responses in newborns and young infants during respiratory viral...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $100,228 on February 18, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop mechanistic models and machine learning approaches that predict how STAT signaling dynamics and promoter sequence features together determine gene-specific inflammatory responses. The funded project, titled "Linking Signaling to Gene Expression with Mechanistic Modeling and Machine...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $641,889 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a molecular taxonomy for immune-mediated diseases using machine-learning approaches. The funded research addresses the clinical limitation of relying on disease phenotype alone for diagnosis and treatment selection. The project will apply machine-learning tools—including SIDER (Significant...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $100,228 on November 27, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate extrafollicular memory B cell responses during influenza infection. The project uses single-cell CITE-seq with antigen barcoding to characterize B cells isolated from influenza virus-infected subjects, testing the hypothesis that extrafollicular responses generate broadly reactive...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $182,618 on May 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct genomic epidemiology of human metapneumovirus in the United States. The research project will establish the largest prospective population-based human metapneumovirus genomic epidemiologic study using a large collection of HMPV-positive clinical samples with corresponding patient data from...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital Corporation, doing business as Boston Children's Hospital, $727,080 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 1, 2026. The award funds investigation of age-specific mechanisms of action for three newly discovered adjuvant combinations using human in vitro models and age-specific in vivo models. The research addresses the burden of respiratory infections at extremes of...
The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $162,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mucosal and peripheral immune correlates of protection against pediatric influenza virus. The research defines immunological predictors of diverse influenza outcomes in pediatric populations using immunomic, functional, and computational approaches. The study addresses two primary questions: what circulating and mucosal-associated immune responses predict influenza outcomes in children, and whether measures of circulating immunity can serve as surrogates for mucosal protection. This work builds on the principal investigator's prior postdoctoral research demonstrating that innate and T cell populations outperform traditional serology in predicting symptomatic influenza risk in adults. The pediatric focus addresses a gap in knowledge, as existing correlates of protection are derived largely from adult studies and their applicability to children remains unknown. The project runs from September 1, 2026 through August 31, 2028 and is performed in Pittsburgh, Pennsylvania. The award is a Project Grant, an assistance type supporting investigator-initiated research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $162.0k | 9/1/26 |